Report: COVID-19 Vaccine Makers Tout Early Trial Data To Boost Stocks

By Ariel Cohen / August 19, 2020 at 5:41 PM

Drug companies developing COVID-19 vaccines with taxpayer funds are using the news of their government awards and early trial results to boost stock prices and raise profits even though their vaccines are not yet proven, a new report from Lower Drug Prices Now alleges.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.